Skip to content
Toggle Navigation
HOME
ABOUT
TRIALS
Hemorrhagic Cystitis Clinical Trial
Oral Lichen Planus Trial
Radiation Cystitis Patient Registry
MANAGEMENT
PUBLICATIONS
INVESTORS
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact
Recent News
Radiation Cystitis Registry
Investors
Lipella Pharmaceuticals, Inc
2023-01-31T14:49:57+00:00
Investors
Close Sliding Bar Area
Recent Posts
A Message from Our CEO, Dr. Jonathan Kaufman
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry
Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate
Lipella Pharmaceuticals, Inc.
Phone:
412-894-1853
Email:
Get In Touch Via Email
Reach Out
Investors
Corporate Overview
SEC Filings
Press Releases
Stock Quote
Events & Presentations
Corporate Governance
FAQ’s
Investor Relations Contact
Page load link
Go to Top
Reach Out